Abstract
Background SARS-CoV-2 mutations conferring escape from neutralizing antibodies can arise in immunocompromised patients with prolonged infection, but the conditions that facilitate immune escape are still not fully understood.
Methods We characterized endogenous immune responses, within-host SARS-CoV-2 evolution, and autologous neutralization of the viral variants that arose in five immunocompromised patients with prolonged infection and B cell deficiencies.
Results In two patients treated with the monoclonal antibody bamlanivimab, viral resistance to autologous serum arose early and persisted for several months, accompanied by ongoing evolution in the spike protein. These patients exhibited deficiencies in both T and B cell arms, and one patient succumbed to disease. In contrast, we did not observe spike mutations in immunologically important regions in patients who did not receive exogenous antibodies or who received convalescent plasma and had intact T cell responses to SARS-CoV-2.
Conclusions Our results underscore the potential importance of multiple factors – the absence of an effective endogenous immune response, persistent virus replication, and selective pressure such as single-agent bamlanivimab – in promoting the emergence of SARS-CoV-2 mutations associated with immune evasion. These findings highlight the need for larger clinical studies in immunocompromised populations to better understand the ramifications of different therapies. Our results also confirm that patients with B cell deficiencies can elicit effector T cells and may suggest an important role for T cells in controlling infection, which is relevant to vaccines and therapeutics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by CDC contract 75D30121C10084 under BAA ERR 20-15-2997 (AB, JW, KK, AP), National Institutes of Health (NIH) grant 5UM1AI148576-02 (NR and EMS), the Pediatric Research Alliance Center for Childhood Infections and Vaccines and Childrens Healthcare of Atlanta, and the Emory Woodruff Health Sciences Center COVID-19 Urgent Research Engagement (CURE) Center, made possible by generous philanthropic support from the O. Wayne Rollins Foundation and the William Randolph Hearst Foundation. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the NIH under Award Number K08AI139348 (AP) and NIH contract No. 75N9301900065 (DW). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the institutional review board at Emory University under protocols STUDY00000260, 00022371, and 00045821. Clinical data was obtained by electronic medical review. Residual nasopharyngeal (NP) swab and serum samples were obtained from the Emory Medical Labs. Whole blood samples were obtained after patient enrollment and consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All sequence data (cleaned of human reads) are available on NCBI under BioProject PRJNA634356. SARS-CoV-2 consensus sequences are available in GISAID under accession numbers EPI_ISL_1503958 and EPI_ISL_6913932-43.
